Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) Stock Competitors & Peer Comparison
See CPRX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for CPRX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CPRX | $31.49 | +0.00% | 3.9B | 12.30 | $2.56 | N/A |
| VRTX | $477.10 | -0.95% | 121.1B | 25.35 | $18.82 | N/A |
| REGN | $762.63 | +3.29% | 78.6B | 16.71 | $45.63 | +0.48% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $853.82 | -3.26% | 54.3B | 78.75 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMDW | $9.57 | -3.14% | 42.7B | -2.32 | -$4.15 | N/A |
| RVMD | $187.53 | -2.41% | 39.9B | -26.52 | -$7.07 | N/A |
| ONC | $316.01 | -1.88% | 33.8B | 70.70 | $4.47 | N/A |
| ALNY | $205.52 | -28.30% | 27.4B | 37.02 | $5.55 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
CPRX vs VRTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, VRTX has a market cap of 121.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while VRTX trades at $477.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas VRTX's P/E ratio is 25.35. In terms of profitability, CPRX's ROE is +0.24%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CPRX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
CPRX vs REGN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, REGN has a market cap of 78.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while REGN trades at $762.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas REGN's P/E ratio is 16.71. In terms of profitability, CPRX's ROE is +0.24%, compared to REGN's ROE of +0.18%. Regarding short-term risk, CPRX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
CPRX vs VRNA Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CPRX's ROE is +0.24%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CPRX is similarly volatile compared to VRNA. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
CPRX vs ARGX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ARGX has a market cap of 54.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ARGX trades at $853.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ARGX's P/E ratio is 78.75. In terms of profitability, CPRX's ROE is +0.24%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, CPRX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
CPRX vs SGEN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CPRX's ROE is +0.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CPRX is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check SGEN's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
CPRX vs RVMDW Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RVMDW has a market cap of 42.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RVMDW trades at $9.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RVMDW's P/E ratio is -2.32. In terms of profitability, CPRX's ROE is +0.24%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, CPRX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
CPRX vs RVMD Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RVMD has a market cap of 39.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RVMD trades at $187.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RVMD's P/E ratio is -26.52. In terms of profitability, CPRX's ROE is +0.24%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CPRX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
CPRX vs ONC Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ONC has a market cap of 33.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ONC trades at $316.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ONC's P/E ratio is 70.70. In terms of profitability, CPRX's ROE is +0.24%, compared to ONC's ROE of +0.12%. Regarding short-term risk, CPRX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
CPRX vs ALNY Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ALNY has a market cap of 27.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ALNY trades at $205.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ALNY's P/E ratio is 37.02. In terms of profitability, CPRX's ROE is +0.24%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, CPRX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
CPRX vs ROIV Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ROIV has a market cap of 24.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ROIV trades at $33.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ROIV's P/E ratio is -34.86. In terms of profitability, CPRX's ROE is +0.24%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CPRX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
CPRX vs INCY Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, INCY has a market cap of 24.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while INCY trades at $119.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas INCY's P/E ratio is 16.06. In terms of profitability, CPRX's ROE is +0.24%, compared to INCY's ROE of +0.30%. Regarding short-term risk, CPRX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
CPRX vs BNTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BNTX has a market cap of 22.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BNTX trades at $90.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BNTX's P/E ratio is -19.61. In terms of profitability, CPRX's ROE is +0.24%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CPRX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
CPRX vs UTHR Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, UTHR has a market cap of 22B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while UTHR trades at $517.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas UTHR's P/E ratio is 19.10. In terms of profitability, CPRX's ROE is +0.24%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CPRX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check UTHR's competition here
Moderna, Inc. (NASDAQ: MRNA)
CPRX vs MRNA Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MRNA has a market cap of 21.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MRNA trades at $54.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MRNA's P/E ratio is -6.73. In terms of profitability, CPRX's ROE is +0.24%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, CPRX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MRNA's competition here
Insmed Incorporated (NASDAQ: INSM)
CPRX vs INSM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, INSM has a market cap of 21.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while INSM trades at $98.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas INSM's P/E ratio is -17.15. In terms of profitability, CPRX's ROE is +0.24%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CPRX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
CPRX vs BGNE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CPRX's ROE is +0.24%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CPRX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
CPRX vs DNA-WT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CPRX's ROE is +0.24%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CPRX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check DNA-WT's competition here
Genmab A/S (NASDAQ: GMAB)
CPRX vs GMAB Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, GMAB has a market cap of 17.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while GMAB trades at $28.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas GMAB's P/E ratio is 20.77. In terms of profitability, CPRX's ROE is +0.24%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CPRX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check GMAB's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
CPRX vs NBIX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, NBIX has a market cap of 16.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while NBIX trades at $166.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas NBIX's P/E ratio is 24.10. In terms of profitability, CPRX's ROE is +0.24%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, CPRX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
CPRX vs JAZZ Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, JAZZ has a market cap of 15.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while JAZZ trades at $252.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas JAZZ's P/E ratio is 19.66. In terms of profitability, CPRX's ROE is +0.24%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CPRX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check JAZZ's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
CPRX vs BBIO Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BBIO has a market cap of 15.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BBIO trades at $80.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BBIO's P/E ratio is -21.41. In terms of profitability, CPRX's ROE is +0.24%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CPRX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
CPRX vs ASND Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ASND has a market cap of 15.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ASND trades at $243.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ASND's P/E ratio is -100.79. In terms of profitability, CPRX's ROE is +0.24%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CPRX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ASND's competition here
Exelixis, Inc. (NASDAQ: EXEL)
CPRX vs EXEL Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, EXEL has a market cap of 13.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while EXEL trades at $53.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas EXEL's P/E ratio is 15.88. In terms of profitability, CPRX's ROE is +0.24%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CPRX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check EXEL's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
CPRX vs KRTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CPRX's ROE is +0.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CPRX is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check KRTX's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
CPRX vs ARWR Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ARWR has a market cap of 11.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ARWR trades at $84.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ARWR's P/E ratio is -39.37. In terms of profitability, CPRX's ROE is +0.24%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CPRX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ARWR's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
CPRX vs BMRN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BMRN has a market cap of 11.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BMRN trades at $60.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BMRN's P/E ratio is 28.86. In terms of profitability, CPRX's ROE is +0.24%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CPRX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check BMRN's competition here
Bio-Techne Corporation (NASDAQ: TECH)
CPRX vs TECH Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while TECH trades at $72.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas TECH's P/E ratio is 37.16. In terms of profitability, CPRX's ROE is +0.24%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CPRX is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
CPRX vs RNAM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CPRX's ROE is +0.24%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CPRX is similarly volatile compared to RNAM. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
CPRX vs AXSM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, AXSM has a market cap of 11.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while AXSM trades at $217.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas AXSM's P/E ratio is -56.92. In terms of profitability, CPRX's ROE is +0.24%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CPRX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check AXSM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
CPRX vs MDGL Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MDGL has a market cap of 10.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MDGL trades at $467.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MDGL's P/E ratio is -36.51. In terms of profitability, CPRX's ROE is +0.24%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, CPRX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MDGL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
CPRX vs SMMT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, SMMT has a market cap of 10.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while SMMT trades at $13.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas SMMT's P/E ratio is -8.14. In terms of profitability, CPRX's ROE is +0.24%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, CPRX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check SMMT's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
CPRX vs KRYS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, KRYS has a market cap of 10.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while KRYS trades at $341.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas KRYS's P/E ratio is 45.60. In terms of profitability, CPRX's ROE is +0.24%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CPRX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check KRYS's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
CPRX vs HALO Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, HALO has a market cap of 9.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while HALO trades at $82.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas HALO's P/E ratio is 17.87. In terms of profitability, CPRX's ROE is +0.24%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CPRX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check HALO's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
CPRX vs CYTK Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CYTK trades at $77.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CYTK's P/E ratio is -13.23. In terms of profitability, CPRX's ROE is +0.24%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CPRX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
CPRX vs RXDX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CPRX's ROE is +0.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CPRX is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RXDX's competition here
Abivax S.A. (NASDAQ: ABVX)
CPRX vs ABVX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ABVX has a market cap of 9.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ABVX trades at $124.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ABVX's P/E ratio is -65.48. In terms of profitability, CPRX's ROE is +0.24%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CPRX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ABVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
CPRX vs NUVL Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas NUVL's P/E ratio is -21.79. In terms of profitability, CPRX's ROE is +0.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CPRX is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
CPRX vs CRNX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CRNX has a market cap of 8.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CRNX trades at $83.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CRNX's P/E ratio is -16.28. In terms of profitability, CPRX's ROE is +0.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CPRX is less volatile compared to CRNX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
CPRX vs PTGX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, PTGX has a market cap of 8.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while PTGX trades at $136.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas PTGX's P/E ratio is -75.49. In terms of profitability, CPRX's ROE is +0.24%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CPRX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
CPRX vs IMGN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CPRX's ROE is +0.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CPRX is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check IMGN's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
CPRX vs IONS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, IONS has a market cap of 8.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while IONS trades at $51.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas IONS's P/E ratio is -30.10. In terms of profitability, CPRX's ROE is +0.24%, compared to IONS's ROE of -1.11%. Regarding short-term risk, CPRX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check IONS's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
CPRX vs PRAX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, PRAX has a market cap of 8.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while PRAX trades at $307.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas PRAX's P/E ratio is -23.02. In terms of profitability, CPRX's ROE is +0.24%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CPRX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
CPRX vs SYRE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, SYRE has a market cap of 8.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while SYRE trades at $98.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas SYRE's P/E ratio is -47.27. In terms of profitability, CPRX's ROE is +0.24%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CPRX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check SYRE's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
CPRX vs KYMR Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, KYMR has a market cap of 8.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while KYMR trades at $103.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas KYMR's P/E ratio is -29.29. In terms of profitability, CPRX's ROE is +0.24%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CPRX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check KYMR's competition here
Alkermes plc (NASDAQ: ALKS)
CPRX vs ALKS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ALKS has a market cap of 8.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ALKS trades at $48.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ALKS's P/E ratio is 52.66. In terms of profitability, CPRX's ROE is +0.24%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, CPRX is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ALKS's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
CPRX vs BPMC Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CPRX's ROE is +0.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CPRX is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
CPRX vs APGE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while APGE trades at $134.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas APGE's P/E ratio is -30.97. In terms of profitability, CPRX's ROE is +0.24%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CPRX is less volatile compared to APGE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check APGE's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
CPRX vs CERE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CERE's P/E ratio is -16.47. In terms of profitability, CPRX's ROE is +0.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CPRX is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
CPRX vs TGTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, TGTX has a market cap of 8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while TGTX trades at $52.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas TGTX's P/E ratio is 17.88. In terms of profitability, CPRX's ROE is +0.24%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CPRX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check TGTX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
CPRX vs IMVT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, IMVT has a market cap of 7.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while IMVT trades at $38.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas IMVT's P/E ratio is -14.46. In terms of profitability, CPRX's ROE is +0.24%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CPRX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check IMVT's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
CPRX vs PCVX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, PCVX has a market cap of 7.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while PCVX trades at $54.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas PCVX's P/E ratio is -7.86. In terms of profitability, CPRX's ROE is +0.24%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CPRX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check PCVX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
CPRX vs IBRX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, IBRX has a market cap of 7.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while IBRX trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas IBRX's P/E ratio is -8.44. In terms of profitability, CPRX's ROE is +0.24%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CPRX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check IBRX's competition here
Metsera, Inc. (NASDAQ: MTSR)
CPRX vs MTSR Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CPRX's ROE is +0.24%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CPRX is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MTSR's competition here
Merus N.V. (NASDAQ: MRUS)
CPRX vs MRUS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CPRX's ROE is +0.24%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, CPRX is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
CPRX vs RYTM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RYTM trades at $99.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RYTM's P/E ratio is -31.71. In terms of profitability, CPRX's ROE is +0.24%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CPRX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
CPRX vs ACLX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CPRX's ROE is +0.24%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CPRX is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ACLX's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
CPRX vs COGT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, COGT has a market cap of 6.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while COGT trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas COGT's P/E ratio is -18.45. In terms of profitability, CPRX's ROE is +0.24%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CPRX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check COGT's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
CPRX vs RETA Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RETA's P/E ratio is -66.29. In terms of profitability, CPRX's ROE is +0.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CPRX is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RETA's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
CPRX vs MIRM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MIRM has a market cap of 6.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MIRM trades at $105.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MIRM's P/E ratio is -7.78. In terms of profitability, CPRX's ROE is +0.24%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CPRX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MIRM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
CPRX vs BLTE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, BLTE has a market cap of 6.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while BLTE trades at $158.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas BLTE's P/E ratio is -84.82. In terms of profitability, CPRX's ROE is +0.24%, compared to BLTE's ROE of -0.18%. Regarding short-term risk, CPRX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check BLTE's competition here
Erasca, Inc. (NASDAQ: ERAS)
CPRX vs ERAS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ERAS has a market cap of 6.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ERAS trades at $18.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ERAS's P/E ratio is -19.51. In terms of profitability, CPRX's ROE is +0.24%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CPRX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ERAS's competition here
CG Oncology Inc. (NASDAQ: CGON)
CPRX vs CGON Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CGON has a market cap of 6.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CGON trades at $71.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CGON's P/E ratio is -30.55. In terms of profitability, CPRX's ROE is +0.24%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CPRX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CGON's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
CPRX vs CNTA Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CPRX's ROE is +0.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CPRX is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check CNTA's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
CPRX vs XENE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, XENE has a market cap of 6.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while XENE trades at $62.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas XENE's P/E ratio is -13.33. In terms of profitability, CPRX's ROE is +0.24%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CPRX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
CPRX vs LGND Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while LGND trades at $287.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas LGND's P/E ratio is 34.48. In terms of profitability, CPRX's ROE is +0.24%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CPRX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CPRX vs SRRK Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, SRRK has a market cap of 5.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while SRRK trades at $47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas SRRK's P/E ratio is -13.17. In terms of profitability, CPRX's ROE is +0.24%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CPRX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check SRRK's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
CPRX vs PTCT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, PTCT has a market cap of 5.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while PTCT trades at $68.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas PTCT's P/E ratio is -29.19. In terms of profitability, CPRX's ROE is +0.24%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, CPRX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check PTCT's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
CPRX vs CDTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CPRX's ROE is +0.24%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CPRX is similarly volatile compared to CDTX. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check CDTX's competition here
Abcam plc (NASDAQ: ABCM)
CPRX vs ABCM Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CPRX's ROE is +0.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CPRX is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
CPRX vs ISEE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CPRX's ROE is +0.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CPRX is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
CPRX vs APLS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas APLS's P/E ratio is 38.35. In terms of profitability, CPRX's ROE is +0.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CPRX is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check APLS's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
CPRX vs TVTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, TVTX has a market cap of 5.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while TVTX trades at $55.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas TVTX's P/E ratio is -254.05. In terms of profitability, CPRX's ROE is +0.24%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CPRX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
CPRX vs TERN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas TERN's P/E ratio is -51.41. In terms of profitability, CPRX's ROE is +0.24%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CPRX is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check TERN's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
CPRX vs DFTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, DFTX has a market cap of 4.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while DFTX trades at $43.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas DFTX's P/E ratio is N/A. In terms of profitability, CPRX's ROE is +0.24%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, CPRX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check DFTX's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
CPRX vs DYN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, DYN has a market cap of 4.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while DYN trades at $25.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas DYN's P/E ratio is -7.82. In terms of profitability, CPRX's ROE is +0.24%, compared to DYN's ROE of -0.64%. Regarding short-term risk, CPRX is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check DYN's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
CPRX vs CRSP Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CRSP has a market cap of 4.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CRSP trades at $47.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CRSP's P/E ratio is -9.39. In terms of profitability, CPRX's ROE is +0.24%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CPRX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CRSP's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
CPRX vs FOLD Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CPRX's ROE is +0.24%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CPRX is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
CPRX vs AKRO Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CPRX's ROE is +0.24%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CPRX is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check AKRO's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
CPRX vs DNTH Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, DNTH has a market cap of 4.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while DNTH trades at $106.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas DNTH's P/E ratio is -25.89. In terms of profitability, CPRX's ROE is +0.24%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CPRX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check DNTH's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
CPRX vs ALPN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CPRX's ROE is +0.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CPRX is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ALPN's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
CPRX vs ACAD Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ACAD has a market cap of 4.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ACAD trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ACAD's P/E ratio is 12.68. In terms of profitability, CPRX's ROE is +0.24%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CPRX is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ACAD's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
CPRX vs CAI Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CAI has a market cap of 4.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CAI trades at $15.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CAI's P/E ratio is -86.19. In terms of profitability, CPRX's ROE is +0.24%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CPRX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CAI's competition here
Veradermics, Incorporated (NYSE: MANE)
CPRX vs MANE Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MANE trades at $105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MANE's P/E ratio is -33.36. In terms of profitability, CPRX's ROE is +0.24%, compared to MANE's ROE of -0.84%. Regarding short-term risk, CPRX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MANE's competition here
Opthea Limited (NASDAQ: OPT)
CPRX vs OPT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas OPT's P/E ratio is -1.52. In terms of profitability, CPRX's ROE is +0.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CPRX is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
CPRX vs PRTC Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas PRTC's P/E ratio is -3.78. In terms of profitability, CPRX's ROE is +0.24%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, CPRX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check PRTC's competition here
Celcuity Inc. (NASDAQ: CELC)
CPRX vs CELC Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CELC has a market cap of 4.2B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CELC trades at $86.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CELC's P/E ratio is -22.15. In terms of profitability, CPRX's ROE is +0.24%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CPRX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CELC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
CPRX vs EWTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, EWTX has a market cap of 4.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while EWTX trades at $38.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas EWTX's P/E ratio is -23.15. In terms of profitability, CPRX's ROE is +0.24%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CPRX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check EWTX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
CPRX vs MRTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CPRX's ROE is +0.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CPRX is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check MRTX's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
CPRX vs ELVN Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ELVN has a market cap of 3.9B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ELVN trades at $54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ELVN's P/E ratio is -32.82. In terms of profitability, CPRX's ROE is +0.24%, compared to ELVN's ROE of -0.21%. Regarding short-term risk, CPRX is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ELVN's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
CPRX vs RYZB Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RYZB's P/E ratio is -57.86. In terms of profitability, CPRX's ROE is +0.24%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, CPRX is less volatile compared to RYZB. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
CPRX vs CBAY Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas CBAY's P/E ratio is -32.81. In terms of profitability, CPRX's ROE is +0.24%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, CPRX is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check CBAY's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
CPRX vs VKTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while VKTX trades at $31.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas VKTX's P/E ratio is -7.67. In terms of profitability, CPRX's ROE is +0.24%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, CPRX is less volatile compared to VKTX. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
CPRX vs DNLI Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, DNLI has a market cap of 3.7B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while DNLI trades at $23.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas DNLI's P/E ratio is -7.99. In terms of profitability, CPRX's ROE is +0.24%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CPRX is less volatile compared to DNLI. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check DNLI's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
CPRX vs ORKA Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ORKA has a market cap of 3.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ORKA trades at $96.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ORKA's P/E ratio is -49.75. In terms of profitability, CPRX's ROE is +0.24%, compared to ORKA's ROE of -0.26%. Regarding short-term risk, CPRX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ORKA's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
CPRX vs ADPT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ADPT has a market cap of 3.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ADPT trades at $22.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ADPT's P/E ratio is -41.80. In terms of profitability, CPRX's ROE is +0.24%, compared to ADPT's ROE of -0.31%. Regarding short-term risk, CPRX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ADPT's competition here
Alumis Inc. (NASDAQ: ALMS)
CPRX vs ALMS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ALMS has a market cap of 3.6B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ALMS trades at $28.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ALMS's P/E ratio is -7.39. In terms of profitability, CPRX's ROE is +0.24%, compared to ALMS's ROE of -0.55%. Regarding short-term risk, CPRX is less volatile compared to ALMS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ALMS's competition here
Arcus Biosciences, Inc. (NYSE: RCUS)
CPRX vs RCUS Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, RCUS has a market cap of 3.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while RCUS trades at $28.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas RCUS's P/E ratio is -8.66. In terms of profitability, CPRX's ROE is +0.24%, compared to RCUS's ROE of -0.69%. Regarding short-term risk, CPRX is less volatile compared to RCUS. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check RCUS's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
CPRX vs SWTX Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas SWTX's P/E ratio is -13.78. In terms of profitability, CPRX's ROE is +0.24%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, CPRX is similarly volatile compared to SWTX. This indicates similar risk in terms of short-term price fluctuations for CPRX.Check SWTX's competition here
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT)
CPRX vs ARQT Comparison August 2026
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CPRX stands at 3.9B. In comparison, ARQT has a market cap of 3.5B. Regarding current trading prices, CPRX is priced at $31.49 on the NASDAQ, while ARQT trades at $26.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CPRX currently has a P/E ratio of 12.30, whereas ARQT's P/E ratio is -933.00. In terms of profitability, CPRX's ROE is +0.24%, compared to ARQT's ROE of -0.01%. Regarding short-term risk, CPRX is less volatile compared to ARQT. This indicates lower risk in terms of short-term price fluctuations for CPRX.Check ARQT's competition here